Grant: Engage Grants Program
Université de Sherbrooke
$25,000.00
Development of robust and flexible assays for PARP-1
EF 2013-14
Résumé
CanAm Bioresearch is developing a new class of bi-functional pyridoxine-based molecules that blockpoly(ADP ribose) polymerase 1 (PARP) and the vascular endothelial growth factor receptor (VEGFR). PARPsignals damaged DNA by adding ADP polymers on proteins, and is important for DNA repair. The VEGFRsystem participates in neo-vascularization. CanAm lacks expertise in enzymology and in the biology of PARP,which is an essential step to develop effective PARP-directed inhibitors. Our laboratory has extensive expertisein assaying enzymes and in developing biochemical tools for their study. Furthermore, our currentlyNSERC-funded project (355388-2010) involves the study of PARP. Therefore, a partnership with CanAm is aperfect fit in which we will provide the much-needed expertise to the characterization of PARP inhibitors. Wepropose to support the characterization of this new class of molecules by developing various PARP assays.Specifically, we will 1) screen the CanAm molecule panel and determine the kinetics inhibition, and 2)characterize hit molecules by assessing various aspect of PARP biology including its auto-modification,histone modification, DNA binding, and subcellular localization. For the project, CanAm will provide series ofPARP inhibitors and our group will perform the kinetic analyses and biochemical characterization. Our grouphas developed extensive expertise in working with enzymes, developing activation and inhibition assays,enzyme biochemistry and protein engineering. Therefore, we are perfectly suited to assist CanAm. By the sametoken, our group will benefit from the enrichment of our expertise in studying the fundamentals of PARP, aprotein that interest us because of its role in apoptosis as a substrate of caspases. This industry-academicpartnership will strengthen the capability of CanAm to provide novel treatments and our ability to performcutting edge research in biochemistry. This project will also serve as a starting point for long-termcollaboration between parties, which will lead to the training of HQPs in Canada.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
460794-2013
Name nom
DeMontigny, David
Department département
Pharmacologie
Organization id
68
Institution établissement
Université de Sherbrooke
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2013
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
1200
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Advancement of knowledge
Area of application fr
Avancement des connaissances
Research subject code
5100
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Cell biology
Research subject fr
Biologie cellulaire
Partie
1
Nb partie
1
Application title
Development of robust and flexible assays for PARP-1
Keyword
NSERC
Application summary
CanAm Bioresearch is developing a new class of bi-functional pyridoxine-based molecules that blockpoly(ADP ribose) polymerase 1 (PARP) and the vascular endothelial growth factor receptor (VEGFR). PARPsignals damaged DNA by adding ADP polymers on proteins, and is important for DNA repair. The VEGFRsystem participates in neo-vascularization. CanAm lacks expertise in enzymology and in the biology of PARP,which is an essential step to develop effective PARP-directed inhibitors. Our laboratory has extensive expertisein assaying enzymes and in developing biochemical tools for their study. Furthermore, our currentlyNSERC-funded project (355388-2010) involves the study of PARP. Therefore, a partnership with CanAm is aperfect fit in which we will provide the much-needed expertise to the characterization of PARP inhibitors. Wepropose to support the characterization of this new class of molecules by developing various PARP assays.Specifically, we will 1) screen the CanAm molecule panel and determine the kinetics inhibition, and 2)characterize hit molecules by assessing various aspect of PARP biology including its auto-modification,histone modification, DNA binding, and subcellular localization. For the project, CanAm will provide series ofPARP inhibitors and our group will perform the kinetic analyses and biochemical characterization. Our grouphas developed extensive expertise in working with enzymes, developing activation and inhibition assays,enzyme biochemistry and protein engineering. Therefore, we are perfectly suited to assist CanAm. By the sametoken, our group will benefit from the enrichment of our expertise in studying the fundamentals of PARP, aprotein that interest us because of its role in apoptosis as a substrate of caspases. This industry-academicpartnership will strengthen the capability of CanAm to provide novel treatments and our ability to performcutting edge research in biochemistry. This project will also serve as a starting point for long-termcollaboration between parties, which will lead to the training of HQPs in Canada.